Developer docs
API playgroundTry for free, no card

Search company profiles

Glycotope Biotechnology

Full company profile

uuid000bdvv

Namestring
Glycotope Biotechnology
Legal namestring
e-pixler NEW MEDIA GmbH
Websiteurl
glycotope.com
Company typeenum
Private
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHeidelberg, Germany
HQ citystring
Heidelberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
drug development, bioengineering research, biopharmaceutical development, therapeutic research, biotechnology innovation
Industry2 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical R&D
Social media profiles1 record
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Glycotope Biotechnology is described as a Drug Development and BioEngineering company, indicating it conducts biopharmaceutical research and development activities. The firmographics place it in the biotechnology sector with operations based in Heidelberg, Germany. The provided input does not include product-specific, technology-specific, or pipeline-specific details.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche is a global biopharmaceutical leader with one of the largest biologics pipelines — broadly comparable as a backdrop incumbent for glyco-engineered/biological therapeutics commercialization and as a likely partner/acquirer for Glycotope-type assets.

TypeEmerging player
Description

AbCellera is a Canadian antibody discovery and development company leveraging a high-throughput single-cell platform — relevant as an emerging technology-driven biologics developer with comparable platform-leveraging model.

TypeRegional player
Description

Evotec is a Germany-headquartered drug discovery and development services company with a strong biologics/protein engineering offering, providing a relevant regional comparand for platform-enabled biologics development.

TypeDirect peer
Description

MacroGenics is a US clinical-stage biotech developing engineered antibody-based therapeutics, including ADCs and bispecifics — closely comparable in the bioengineered biologics drug development niche that Glycotope occupies.

TypeDirect peer
Description

argenx is a Belgium-based biotech focused on engineered antibody therapeutics with a strong immunology pipeline, providing a clear comparand for Glycotope's biologics development approach and target product profile strategy.

TypeDirect peer
Description

Genmab is a Denmark-based biotech developing differentiated antibody therapeutics, with proprietary technology platforms for engineering antibodies — directly comparable to Glycotope's bioengineering-led, antibody-based drug development model.

TypeDirect peer
Description

BioInvent is a Sweden-based clinical-stage biotech developing tumor-directed antibody therapeutics using proprietary technology platforms — comparable in stage, modality, and platform-based drug development approach.

TypeOthers
Description

Lonza is a Swiss-headquartered global CDMO with deep biologics manufacturing capabilities — adjacent comparand relevant to Glycotope's CMC/bioprocessing requirements and potential manufacturing partner ecosystem.

TypeDirect peer
Description

MorphoSys is a German antibody-discovery and development biotech historically based near Munich — directly comparable in geography and in focus on antibody therapeutics, with overlapping technology and pipeline profiles to Glycotope.

10Merck KGaA
TypeBroad incumbent
Description

Merck KGaA is a German-headquartered science and technology company with significant biopharma and life-science tools activity (including Sigma-Aldrich), providing a relevant regional incumbent comparand for both therapeutics and bioengineering services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Glycotope Biotechnology

Biopharmaceutical R&Dglycotope.com

Glycotope Biotechnology firmographics

Firmographics
Name
Glycotope Biotechnology
Legal name
e-pixler NEW MEDIA GmbH
Website
https://glycotope.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Glycotope Biotechnology industry classification

Industry
Product category
Biopharmaceutical R&D
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug development
  • Bioengineering research
  • Biopharmaceutical development
  • Therapeutic research
  • Biotechnology innovation

Where Glycotope Biotechnology is headquartered

Location

Headquarters

HQ city
Heidelberg
HQ country
Germany
HQ region
Europe

Markets served

Glycotope Biotechnology business model

Business model
GTM type
B2B
Offering type
Services

Glycotope Biotechnology product offering

Product offering

Core offering

Glycotope Biotechnology is described as a Drug Development and BioEngineering company, indicating it conducts biopharmaceutical research and development activities. The firmographics place it in the biotechnology sector with operations based in Heidelberg, Germany. The provided input does not include product-specific, technology-specific, or pipeline-specific details.

Differentiator

Problem solved

Functional benefit

Glycotope Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Glycotope Biotechnology partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Glycotope Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Roche: Roche is a global biopharmaceutical leader with one of the largest biologics pipelines — broadly comparable as a backdrop incumbent for glyco-engineered/biological therapeutics commercialization and as a likely partner/acquirer for Glycotope-type assets.
  • Merck KGaA: Merck KGaA is a German-headquartered science and technology company with significant biopharma and life-science tools activity (including Sigma-Aldrich), providing a relevant regional incumbent comparand for both therapeutics and bioengineering services.

Emerging players

  • AbCellera Biologics: AbCellera is a Canadian antibody discovery and development company leveraging a high-throughput single-cell platform — relevant as an emerging technology-driven biologics developer with comparable platform-leveraging model.

Regional players

  • Evotec: Evotec is a Germany-headquartered drug discovery and development services company with a strong biologics/protein engineering offering, providing a relevant regional comparand for platform-enabled biologics development.

Direct peers

  • MacroGenics: MacroGenics is a US clinical-stage biotech developing engineered antibody-based therapeutics, including ADCs and bispecifics — closely comparable in the bioengineered biologics drug development niche that Glycotope occupies.
  • argenx: argenx is a Belgium-based biotech focused on engineered antibody therapeutics with a strong immunology pipeline, providing a clear comparand for Glycotope's biologics development approach and target product profile strategy.
  • Genmab: Genmab is a Denmark-based biotech developing differentiated antibody therapeutics, with proprietary technology platforms for engineering antibodies — directly comparable to Glycotope's bioengineering-led, antibody-based drug development model.
  • BioInvent International: BioInvent is a Sweden-based clinical-stage biotech developing tumor-directed antibody therapeutics using proprietary technology platforms — comparable in stage, modality, and platform-based drug development approach.
  • MorphoSys: MorphoSys is a German antibody-discovery and development biotech historically based near Munich — directly comparable in geography and in focus on antibody therapeutics, with overlapping technology and pipeline profiles to Glycotope.

Others

  • Lonza Group: Lonza is a Swiss-headquartered global CDMO with deep biologics manufacturing capabilities — adjacent comparand relevant to Glycotope's CMC/bioprocessing requirements and potential manufacturing partner ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

Glycotope Biotechnology social profiles

Digital presence

Glycotope Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Glycotope Biotechnology leadership team

Management profile

Number of profiles

Glycotope Biotechnology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Glycotope Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glycotope Biotechnology

What does Glycotope Biotechnology do?

Glycotope Biotechnology is described as a Drug Development and BioEngineering company, indicating it conducts biopharmaceutical research and development activities. The firmographics place it in the biotechnology sector with operations based in Heidelberg, Germany. The provided input does not include product-specific, technology-specific, or pipeline-specific details.

Is Glycotope Biotechnology a public or private company?

Glycotope Biotechnology is a private company. It is classified as unknown and is currently operating.

When was Glycotope Biotechnology founded?

Glycotope Biotechnology was founded in 2001. It employs 51 to 100 people.

Where is Glycotope Biotechnology based?

Glycotope Biotechnology is headquartered in Heidelberg, Germany, in the Europe region.

Who are Glycotope Biotechnology's main competitors?

Broad incumbents on record are Roche and Merck KGaA. AbCellera Biologics is listed as an emerging player. Evotec is listed as a regional player. Direct peers are MacroGenics, argenx, Genmab, BioInvent International and MorphoSys. Lonza Group is listed as an others.

Does Glycotope Biotechnology have an API?

No public API is recorded for Glycotope Biotechnology.

What industry is Glycotope Biotechnology in?

Glycotope Biotechnology's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDaiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mDaiichi Sankyo finalized a $132.5m acquisition of gatipotuzumab IP from Glycotope, resolving all remaining obligations under a 2018 licensing deal. The antibody is part of DS-3939, an ADC in Phase I/II trials for solid tumours. The deal reflects the growing ADC market, with DS-3939 using Daiichi's DXd technology.Business Wire BlogDaiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbHDaiichi Sankyo will pay Glycotope $132.5 million to acquire intellectual property rights for the anti-TA-MUC1 antibody gatipotuzumab, which is part of DS-3939, an antibody drug conjugate. The payment satisfies all potential clinical, regulatory, and sales milestone payments and royalties under a 2018 licensing agreement. DS-3939 is being evaluated in a phase 1/2 clinical trial for advanced solid tumors.GlobeNewswireTherabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancerTherabest and Glycotope signed an agreement to assess the combination of Therabest's iPSC-derived NK cell therapy TB-100 and Glycotope's immuno-cytokine GT-00AxIL15 in triple-negative breast cancer patients. The collaboration aims to improve NK cell persistency and cytotoxicity through the immuno-cytokine's tumor targeting.GlobeNewswireLegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug ConjugateLegoChem Biosciences and Glycotope signed a research collaboration and license agreement to develop an antibody drug conjugate combining LCB's ADC technology with Glycotope's investigational tumor-targeting antibodies. LCB would receive worldwide exclusive rights upon a feasibility study, with Glycotope receiving upfront, milestone, and royalty payments, though specific terms were not disclosed.BioSpaceGlycotope to spin-out its Service Business to the newly formed FyoniBio GmbHCantonBio completed its acquisition of Glycotope's service business, spun out as FyoniBio GmbH. The spin-out allows Glycotope to focus solely on drug discovery and development, while FyoniBio continues contract development services. Canton Biologics' CEO said the acquisition supports its international growth strategy.GlobeNewswireGlycotope to spin-out its Service Business to the newlyCantonBio completed its acquisition of Glycotope's service business, which was spun out into FyoniBio GmbH. The spin-out allows Glycotope to focus solely on drug discovery and development, while FyoniBio continues contract development services under Canton Biologics Group.GlobeNewswireByondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargetsByondis and Glycotope entered a platform access agreement to discover and develop antibodies against tumor-specific GlycoTargets. Byondis gained exclusive rights to evaluate and develop these antibodies, with an option to in-license them for ADC development. Specific financial terms were not disclosed.GlobeNewswireGlycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingGlycotope GmbH announced two poster presentations at the 2021 ASCO virtual annual meeting, reporting on the GATTO phase Ib study. The study combined Gatipotuzumab with anti-EGFR antibodies in 50 patients with refractory solid tumors, showing safety and encouraging anti-tumor activity, particularly with Panitumumab.PR NewswireDaiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug ConjugateDaiichi Sankyo Company and Glycotope GmbH entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate combining Daiichi Sankyo's proprietary ADC technology with Glycotope's investigational tumor-associated TA-MUC1 antibody gatipotuzumab. Under the terms, Daiichi Sankyo receives exclusive worldwide rights to develop and commercialize gatipotuzumab as an ADC, while Glycotope is eligible for upfront, clinical, regulatory, and sales milestone payments plus royalties on net sales. The agreement brings Daiichi Sankyo's ADC pipeline to seven novel candidates in development and builds on a previous 2017 option agreement between the two companies.GlobeNewswireDaiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug ConjugateDaiichi Sankyo and Glycotope signed an exclusive worldwide licensing agreement to develop an antibody drug conjugate combining Daiichi Sankyo's ADC technology with Glycotope's gatipotuzumab antibody. Glycotope will receive an upfront payment and milestone royalties, while Daiichi Sankyo gets worldwide exclusive rights. Specific financial terms were not disclosed.